Company Metrics

• 309.75 P/E
• 4.32 P/S
• 2.46 P/B
• -1.197 EPS
• 27.65% Cash ROIC
• 4.66 Cash Ratio
• 0 / 0% Dividend
• 483,115.00 Avg. Vol.
• 88.08M Shares
• 1.766B Market Cap.

Company Description

ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. The company's product line includes Cinryze for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema; and Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Its products in development include C1 esterase inhibitor to identify further therapeutic uses and potential additional indications and other modes of administration for the treatment of HAE and other C1 mediated diseases; a non-toxigenic strain of C. difficile for the treatment and prevention of CDI.; and Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus infections related to transplant. The company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.
less

ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. The company's product line includes Cinryze for routine prophylaxis against angioedema attacks in adolescent and adult patients with h...
more

News